Bangalore, Jun 4 (UNI) Biocon Ltd today announced the launch of a safety device in form of pre-filled syringes for life saving drugs in nephrology and oncology related diseases.
The two products are filled with the developed Granulocyte-colony stimulating factor (GCSF) and Erythropoietin (EPO), respectively.
These products had been launched in collaboration with Safety Syringes Inc of the US.
ERYPRO Safe and NUFIL Safe would be the first two drugs being marketed using this novel device and other injectible products would follow in the future, company CMD Kiran Mazumdar Shaw said.
Speaking at a press conference here, she said the two pre-filled products would offer a painless and safe for patients suffering from kidney failure and cancer, respectively. This self injecting devices would go a long way to help patients with these chronic diseases not to depend on doctor or para medical staff every day.
The ERYPRO Safe costs Rs 715 for a 2000 IU to Rs 2995 for 10,000 IU dose. NUFIL Safe costs Rs 1975 for a dose of 0.5 ml.
Rakesh Bamzai, President (Marketing) said self injecting products were common in developed countries like the US, while it was still in a primitive stage in India. The total market for all pre-filled syringes in the country was to the tune of RS 300 crore and Biocon planned to emerge as the top player in the segment in two to three years.
Ms Shaw said the country had one lakh chronic kidney failure cases diagnosed so far while those suffering without any diagnosis were many folds more. In case of cancer the country was witnessing three million patients added every year.
Biocon, which had many products for treatment of Diabetes will be coming out with a Insulin Pen in the next six months, she added.
UNI RS MSP HVB1511